THE CURRENT STATUS OF IMMUNOMODULATORY APPROACHES IN THE TREATMENT OF CHRONIC HEPATITIS B
Chronic hepatitis B is a major global health concern caused by the hepatitis B virus (HBV) and is associated with persistent liver inflammation, progressive fibrosis, liver cirrhosis, and an increased risk of hepatocellular carcinoma. The development and persistence of chronic HBV infection are determined not only by the biological characteristics of the virus but also by the complex interactions between the virus and the host's innate and adaptive immune responses. Therefore, in addition to suppressing viral replication, the modulation of antiviral immune responses has become an important area of research in the management of chronic hepatitis B. This article reviews the immunopathogenesis of chronic hepatitis B, the role of interferon-alpha-based therapy, and emerging immunotherapeutic strategies investigated in combination with nucleos(t)ide analogues. Particular attention is given to therapeutic vaccines, immune checkpoint inhibitors, and approaches aimed at restoring HBV-specific T-cell responses.
Authors
- Worldly Knowledge Publishing Centre
- Khoshimova Dildora
- Ahmadaliyeva Nasiba
- Zokirov Mironshokh
- Nematov Khondamir
- Eraliyeva Madina
- Mukhiddin Numonjonov
Institutions
- Andijan State Medical Institute (UZ)
- Kokand State University (UZ)
Publication Details
- Journal
- International journal of technology and academic research
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24342787
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00